Department of Neurology, Wuhan Asia General Hospital, Wuhan, China.
Brain Behav. 2023 Apr;13(4):e2920. doi: 10.1002/brb3.2920. Epub 2023 Feb 22.
To investigate the clinical effect of butylphthalide combined with urinary kallidinogenase in the treatment of chronic cerebral circulatory insufficiency (CCCI).
A total of 102 CCCI patients admitted to our hospital from October 2020 to December 2021 were retrospectively enrolled in this study. According to the different therapeutic strategy, the patients were divided into combined group (treated with butylphthalide combined with urinary kallidinogenase, n = 51) and butylphthalide group (treated with butylphthalide, n = 51). Blood flow velocity and cerebral blood flow perfusion before and after treatment between the two groups were compared. The clinical efficacy and adverse events of the two groups were analyzed.
After treatment, the effective rate of the combined group was significantly higher than the butylphthalide group (p = .015). Before treatment, the blood flow velocity of middle cerebral artery (MCA), vertebral artery (VA), basilar artery (BA) were comparable (p > .05, respectively), while after treatment, the blood flow velocity of MCA, VA, and BA in combined group were faster than those in butylphthalide group (p < .001, respectively). Before treatment, the relative cerebral blood flow (rCBF), relative cerebral blood volume (rCBV), relative mean transmit time (rMTT) of the two groups were comparable (p > .05, respectively). After treatment, rCBF and rCBV in combined group were higher than those in butylphthalide group (p < .001, respectively), and rMTT in combined group was lower than that in butylphthalide group (p = .001). The rate of adverse events in the two groups were comparable (p = .558).
Butylphthalide combined with urinary kallidinogenase can improve the clinical symptoms of CCCI patients, and the effect is promising, which is worthy of clinical application.
探讨丁基苯酞联合尿激肽原酶治疗慢性脑循环功能不全（CCCI）的临床效果。
选取 2020 年 10 月至 2021 年 12 月我院收治的 102 例 CCCI 患者进行回顾性研究，根据不同的治疗策略将患者分为联合组（丁基苯酞联合尿激肽原酶治疗，n=51）和丁基苯酞组（丁基苯酞治疗，n=51）。比较两组患者治疗前后的血流速度和脑血流灌注情况，分析两组患者的临床疗效和不良反应发生情况。
治疗后，联合组的有效率显著高于丁基苯酞组（p=0.015）。治疗前，两组患者大脑中动脉（MCA）、椎动脉（VA）、基底动脉（BA）的血流速度比较，差异无统计学意义（p>0.05），治疗后联合组 MCA、VA、BA 的血流速度均快于丁基苯酞组（p<0.001）。治疗前，两组患者的相对脑血流量（rCBF）、相对脑血容量（rCBV）、相对平均通过时间（rMTT）比较，差异无统计学意义（p>0.05），治疗后联合组的 rCBF、rCBV 高于丁基苯酞组（p<0.001），rMTT 低于丁基苯酞组（p=0.001）。两组患者不良反应发生率比较，差异无统计学意义（p=0.558）。
丁基苯酞联合尿激肽原酶治疗 CCCI 患者的临床症状效果确切，具有较高的应用价值。
